Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary Study

Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary Study

Background: Severe atopic dermatitis (AD) is a complex disease requiring systemic treatment. This study aimed to assess the effectiveness of combined therapy consisting of dupilumab and sublingual dust mite allergen immunotherapy (SLIT-HDM) in patients with severe AD and HDM allergies. Methods: Pati...

Full description

Saved in:

Bibliographic Details
Main Authors:	Agnieszka Bogacz-Piaseczyńska, Andrzej Bożek, Magdalena Krupka-Olek, Aleksandra Kawczyk-Krupka, Jolanta Zalejska-Fiolka, Giorgio Walter Canonica
Format:	Article
Language:	English
Published:	MDPI AG 2024-09-01
Series:	Vaccines
Subjects:	atopic dermatitis immunotherapy dupilumab house dust mites
Online Access:	https://www.mdpi.com/2076-393X/12/9/1046
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

High Prevalence of Lash Collarettes in Patients with Atopic Dermatitis Treated with Dupilumab
by: Ilaria Trave, et al.
Published: (2025-08-01)

Experience with dupilumab in patients with atopic dermatitis
by: E. A. Glukhova, et al.
Published: (2023-07-01)

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01)

Indoor endotoxin and house dust mite concentrations in the canine homologue of human atopic dermatitis
by: Yunji Song, et al.
Published: (2025-06-01)

The Effect of Dupilumab on Growth Parameters in Pediatric Atopic Dermatitis Patients
by: Vincenzo Piccolo, et al.
Published: (2025-07-01)

New Era in Atopic Dermatitis Treatment: Results of Long-Term Dupilumab Administration
by: Nikolay N. Murashkin, et al.
Published: (2021-11-01)

Differences in immunological profile in atopic dermatitis patients with and without dupilumab therapy
by: Jarmila Čelakovská, et al.
Published: (2025-01-01)

Dupilumab for the treatment of atopic dermatitis and alopecia areata with incidental improvement of trachyonychia
by: Dana H. Chung, BA, et al.
Published: (2025-09-01)

The application of the biological treatment in atopic dermatitis: focus on dupilumab
by: Yu. S. Smolkin, et al.
Published: (2023-03-01)

Metabolomic and Lipidomic Alterations in Patients with Atopic Dermatitis with Dupilumab-Associated Ocular Surface Disease
by: VijayKumar Patra, et al.
Published: (2025-05-01)

Efficacy of dupilumab plus topical corticosteroids in children with atopic dermatitis: A meta‐analysis of randomized controlled trials
by: Li Wang, et al.
Published: (2024-01-01)

Pretreatment Demodex infestation predicts dupilumab-associated blepharoconjunctivitis in atopic dermatitis
by: Paulina Stepinska, et al.
Published: (2025-12-01)

Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis
by: Mohamed A. Kamal, et al.
Published: (2024-11-01)

New Opportunities of Dupilumab in Achieving Disease Control in Preschool Age Patients with Atopic Dermatitis: Clinical Case
by: Julia G. Levina, et al.
Published: (2024-09-01)

The novel house dust mite allergen Der p 39 exacerbates atopic dermatitis-like inflammation in mice by inducing skin barrier dysfunction
by: Shan Liu, BSc, et al.
Published: (2025-03-01)

Successful Dupilumab Administration in Adolescent with Alopecia Areata and Atopic Dermatitis: Clinical Case
by: Eduard T. Ambarchyan, et al.
Published: (2024-09-01)

Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China
by: Yue Xu, et al.
Published: (2025-07-01)

An open-label interventional clinical study evaluating sweating function in dupilumab treatment for atopic dermatitis
by: Mai Matsumoto, et al.
Published: (2025-06-01)

Dupilumab and atopic march; Reduction of incident allergic events or Clinical control?
by: Jorge Sánchez, et al.
Published: (2024-12-01)

Comparative Analysis of the Efficacy of Abrocitinib and Dupilumab in the Treatment of Atopic Dermatitis
by: Song D, et al.
Published: (2025-04-01)

Dupilumab Efficacy and Safety in Severe Atopic Dermatitis in Children under 6 Years of Age: Two Clinical Cases
by: Nikolay N. Murashkin, et al.
Published: (2023-11-01)

Response to Comments on The Association of Inflammatory Indexes Derived From Peripheral Blood Cell Count and Clinical Signs with Response to Treatment with Dupilumab in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis [Response to Letter]
by: Zhang L, et al.
Published: (2025-03-01)

Efficacy and safety of dupilumab in patients with moderate-to-severe atopic dermatitis and comorbid allergic rhinitis
by: Tengfei Tian, et al.
Published: (2025-04-01)

T cell immunophenotypes and IgE responses in patients with moderate‐to‐severe atopic dermatitis receiving dupilumab
by: Davender Redhu, et al.
Published: (2025-05-01)

Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study
by: Filip Rob, et al.
Published: (2025-12-01)

Changes in skin barrier integrity by electrical impedance spectroscopy during dupilumab treatment on a child with severe atopic dermatitis
by: Elif Yaycı, et al.
Published: (2024-11-01)

Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors
by: Francesca Barei, et al.
Published: (2024-12-01)

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study
by: Tiago Torres, et al.
Published: (2025-06-01)

Recurrence and influencing factors of moderate-to-severe atopic dermatitis after dupilumab withdrawal: a retrospective cohort analysis
by: Maohua Chen, et al.
Published: (2025-08-01)

Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE
by: Jonathan I. Silverberg, et al.
Published: (2025-02-01)

Evaluating the Real-World Effectiveness of Systemic Treatments in Atopic Dermatitis Using the Atopic Dermatitis Control Tool (ADCT): A Multi-Centre, Prospective Study
by: Hyun Ji Lee, et al.
Published: (2025-02-01)

Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials
by: Yunqing Sun, et al.
Published: (2025-06-01)

[Pharmacoeconomic Comparison Between Dupilumab and Tralokinumab for the Treatment of Atopic Dermatitis in Italy: A Cost-per-Responder Analysis]
by: Paolo Gisondi, et al.
Published: (2025-05-01)

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2024-04-01)

Atopic dermatitis-induced failure to thrive and hypernatremic dehydration managed with dupilumab in a 5-month-old patient
by: Brooke Walterscheid, MD, et al.
Published: (2025-06-01)

Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network
by: Henner Zirpel, et al.
Published: (2024-12-01)

Real-world safety and effectiveness of dupilumab for the treatment of atopic dermatitis: two-year post-marketing surveillance in Japan
by: Hidehisa Saeki, et al.
Published: (2025-07-01)

Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study
by: Wu Liming, et al.
Published: (2025-12-01)

A clinical case of atopic dermatitis with a rapid positive effect from the use of a genetically engineered biological drug in a teenager
by: E. V. Churyukina, et al.
Published: (2024-05-01)

Clinical Effectiveness, Clinical Stability, and Effects on Serum Galectin-7 Levels of Dupilumab and JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World, Single-Center Analysis
by: Akihiro Horie, et al.
Published: (2025-05-01)